Format

Send to

Choose Destination
Int Immunopharmacol. 2019 Jul 4;74:105729. doi: 10.1016/j.intimp.2019.105729. [Epub ahead of print]

Lessons from next generation influenza vaccines for inflammatory disease therapies.

Author information

1
CEL-SCI Corporation, 8229 Boone Blvd, Vienna, VA 22182, USA.
2
Roseman University of Health Sciences College of Medicine, 10530 Discovery Dr., Las Vegas, NV 89135, USA. Electronic address: ksr@neomed.edu.

Abstract

Lessons can be learned for treating inflammatory diseases such as rheumatoid arthritis (RA) from next generation approaches for development of universal influenza vaccines. Immunomodulation of inflammatory diseases, rather than ablation of cytokine or cellular responses, can address the root cause of the disease and provide potential cure. Like influenza, there are different antigenic 'strains' and inflammatory T cell responses, Th1 or Th17, that drive each person's disease. As such, next generation vaccine-like antigen specific therapies for inflammatory diseases can be developed but will need to be customized to the patient depending upon the antigen and T cell response that is driving the disease.

KEYWORDS:

Immunomodulation; Influenza; Rheumatoid arthritis; T cells; Vaccine therapy

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center